13
Summary of Recommendations
Recommendation # Description
8.1
8.2
8.3
For patients with stage IV NSCLC and driver alterations in
with BRAF V600E mutation
• In the second-line setting, if previous BRAF/MEK
(dabrafenib/trametinib) targeted therapy was given in the
first-line setting, standard treatment based on the ASCO/
OH non-driver mutation guideline should be offered
(Moderate recommendation: IC-L).
• In the second-line setting, if BRAF-targeted therapy was
not given in the first-line setting, dabrafenib/trametinib
may be offered (Moderate recommendation: IC-L) or
dabrafenib or vemurafenib alone may be offered (Weak
recommendation: IC-L).
• If previous chemotherapy, immunotherapy, and/or BRAF-
targeted therapy were given in the first- or subsequent-line
setting, standard treatment based on the ASCO/OH non-
driver mutation guideline should be offered (Moderate
recommendation: IC-L).
8.4 For patients with stage IV NSCLC and driver alterations in
with BRAF mutations other than V600E
• In the second-line setting, standard treatment based on
the ASCO/OH non-driver mutation guideline should be
offered (Moderate recommendation: IC-L).
9.1
9.2
For patients with stage IV NSCLC and MET exon 14 skipping
mutation
• In the first-line setting, for patients with a MET exon 14
skipping mutation MET-targeted therapy with capmatinib
or tepotinib may be offered or standard treatment based
on the ASCO/OH non-driver mutation guideline may be
offered (Moderate recommendation: IC-L).
(cont'd)
